Myelofibrosis – Treatment Access
provincial coverage
Click on the map below for information regarding government reimbursement in your province.
Other coverage
Alberta
Jakavi (ruxolitinib)
- Company:
- Novartis Canada
- Coverage:
- Yes
- Type of coverage:For patients with intermediate to high risk symptomatic
- For patients with intermediate to high risk symptomatic
Myelofibrosis (MF) as assessed using the Dynamic
International Prognostic Scoring System (DIPSS) Plus
or patients with symptomatic splenomegaly. Patients
who have ECOG performance status ≤3 and be either
previously untreated or refractory to other treatment.
Prescribing limited to written authorization by named physicians (see page 33 of the linked document below to review the names of prescribing physicians)Jakavi – Alberta - Outpatient Cancer Drug Benefit Program
Intron A (interferon)
- Company:
- Merck Canada
- Coverage:
- Interferon A 2b is listed on the drug sheet. It does not indicate what coverage is provided for, so it may be worth to see if you can be reimbursed for using it for myelofibrosis.
- Type of coverage:
- Outpatient Cancer Drug Benefit Program
- For more information:
- Drug Coverage List for Alberta
- Alberta Cancer Board
- Provincial Office
- Suite 1220
- 10405 Jasper Avenue
- Edmonton , Alberta
- T5J 3N4
- Tel: (780) 412 6300
- Fax: (780) 412 6326
- info@cancerboard.ab.ca
British Columbia
Jakavi (ruxolitinib)
- Company:
- Novartis Canada
- Coverage:
- Yes
- Type of coverage – as of November 2013
- ruxolitinib BC Cancer coverage
- Intron A (interferon)
- Company:
- Merck Canada
- Coverage:
- Yes
- Type of coverage:
- BC Cancer Agency coverage
- For more information:
- British Columbia Cancer Agency
- Regional Centres:
- Frazer Valley
- Tel: (604) 930 2098
- Toll free: 1 800 523 2885
- Southern Interior
- Tel: (250) 712 3900
- Toll free: 1 888 563 7773
- Vancouver
- Tel: (604) 877 6000
- Toll free: 1 800 663 3333
- Vancouver Island
- Tel: (250) 519 5500
- Toll free: 1 800 670 3322
Manitoba
No coverage at this time
Intron A (interferon)
- Company:
- Merck Canada
- Coverage:
- Yes
- Type of coverage:
- Exception Drug Status (EDS)
- For more information :
- Manitoba Pharmacare Program
- Pharmacare
- Tel: (204) 786 7141
- Toll-free: 1 800 297 8099
- or
- Provincial Drug Programs
- Manitoba Health
- 300 Carlton Street
- Winnipeg, Manitoba
- R3B 3M9
- Tel: (204) 786 7318
New Brunswick
Intron A(interferon)
- Company:
- Merck Canada
- Coverage:
- Yes
- Type of coverage:
- New Brunswick Prescription
Drug Program – Plan AEFGVW
- For more information:
- New Brunswick health program
- New Brunswick Prescription Drug Program
- Tel: (506) 867 4515
- Toll free: 1 800 332 3692
Newfoundland & Labrador
- Intron A (interferon)
- Company:
- Merck Canada
- Coverage:
- Yes
- Type of coverage:
- Special Authorization Drug
- Special Authorization Request Form
- Newfoundland & Labrador Prescription Drug Program
- For more information:
- Newfoundland & Labrador Health Information Centre
- Tel: (709) 757 2409
Northwest Territories
Gleevec (imatinib)
- Company:
- Novartis Canada
- Coverage:
- Yes
- Type of coverage:
- Limited use benefit administer by Alberta Blue Cross
Intron A (interferon)
- Company:
- Merck Canada
- Coverage:
- Yes
- Type of coverage:
- Alberta Blue Cross coverage
- For more information :
- www.hlthss.gov.nt.ca
- Government of the Northwest Territory
- Health Care Coverage
- Toll free: 1 800 661 0830
Nova Scotia
Tasigna (nilotinib)
- Company:
- Novartis Canada
- Coverage:
- Coverage Through Nova Scotia Pharmacare:TASIGNA* is covered by Nova Scotia Pharmacare through the Exception Drug Status (EDS) process according to the following criteria:As a single line agent for the treatment of adults with chronic or accelerated phase CML with resistance or intolerance to prior therapy.This would include:Patients with CML in chronic phase who are intolerant to imatinib or dasatinib or bothPatients with CML in chronic phase who are resistant to imatinib 600mg/dayPatients with CML that have progressed to accelerated phase while on imatinibSequential use of dasatinib and nilotinib is not permitted except in the circumstance described above (i.e. intolerance)
Intron A (interferon)
- Company:
- Merck Canada
- Coverage:
- Yes
- Type of coverage:
- Exception Status for Drug Assistance for Cancer Patients
- Exception Status Drug form
- For information:
- Nova Scotia Pharmacare Programs
- PO Box 500
- Halifax, Nova Scotia
- B3J 2S1
- Toll free: 1 800 544 6191
- Tel: (902) 429 6565
- Fax: (902) 468 9402
Nunavut
Intron A (interferon)
- Company:
- Merck Canada
- Coverage:
- Yes
- Type of coverage:
- NIHB or Extended Health Benefit program #1
- For more information :
- Health and Social Services Website
- Government of Nunavut
- Health Insurance Program
- Toll free: 1 800 661 0833
Ontario
Jakavi (ruxolitinib)
- Company:
- Novartis Canada
- Coverage:
- Yes
- Type of coverage:
- Limited use product
Intron A (interferon)
- Company:
- Merck Canada
- Coverage:
- Yes
- Type of coverage:
- Limited use product
- For more information :
- Ontario Drug Benefit Program
- Ministry INFOline
- Toll free: 1 866 532 3161 (Ontario only)
- TTY: 1 800 387 5559
- Hours of operation
- 8:30am – 5:00pm
Prince Edward Island
Intron A (interferon)
- Company:
- Merck Canada
- Coverage:
- Yes
- Type of coverage:
- Prince Edward Island Drug Formulary
- For more information:
- Prince Edward Island Health Program
- Cancer Assistance Program
- Health Services
- Tel: (902) 838-0955
Quebec
Jakavi (ruxolitinib)
- Company:
- Novartis Canada
- Coverage:
- Yes
- Type of coverage:
- Limited use product
Intron A (interferon)
- Company:
- Merck Canada
- Coverage:
- Yes
- Type of coverage:
- Exception drug status
- For more information:
- Quebec health program
- Régie d’assurance maladie du Québec (RAMQ)
- The Health Insurance Infoline
- 24 hours a day, 7 days a week
- Quebec: (418) 646 4636
- Montreal: (514) 864 3411
- Toll free: 1 800 561 9749
- Agents are available during the following hours:
-
Monday 8:30 a.m. to 4:30 Tuesday 8:30 a.m. to 4:30 Wednesday 10:00 a.m. to 4:30 Thursday 8:30 a.m. to 4:30 Friday 8:30 a.m. to 4:30 - By TDD
- (telecommunication device for the deaf)
- Quebec: (418) 682 3939
- Toll free: 1 800 361 3939
Saskatchewan
Intron A (interferon)
- Company:
- Merck Canada
- Coverage:
- Yes
- Type of coverage:
- Exception Drug Status
- For more information:
- Saskatchewan Cancer Agency
- Saskatchewan Health
- Drug Plan (Prescription)
- Tel: (306) 787 3420
- Toll free: 1 800 667 7581
Yukon
Intron A (interferon)
- Company:
- Merck Canada
- Coverage:
- Yes
- Type of coverage:
- Exception Drug Status
- (under chronic disease program or pharmacare program)
- For more information:
- Yukon Health andSocial Services
- Government of Yukon
- Box 2703
- Whitehorse, Yukon
- Y1A 2C6
- Tel: (867) 667 3673
- Toll free: 1 800-661-0408 local 3673 (Yukon only )
Fax: (867) 667 3096 - hss@gov.yk.ca
Private insurance
For all private insurance go to CHLIA website to find your insurance company. Please note that in the province of Quebec depending on what type of private insurer you have through your employment program, your doctor may not be allowed to override a switch to generic imatinib mesylate. We advise that you review your drug plan policy carefully with regards to the substitution of generic prescription drugs.
Your private insurance will ask for the DIN number of your drug to see if it is covered.
Special Access Program
Health Canada, through its Special Access Programme (SAP), allows doctors to gain access to non-marketed drugs that have not yet been approved for sale in Canada.
The Special Access Programme (SAP) provides access to non-marketed drugs for practitioners treating patients with serious or life-threatening conditions when conventional therapies have failed, are unsuitable, or unavailable. The SAP authorizes a manufacturer to sell a drug that cannot otherwise be sold or distributed in Canada. Drugs considered for release by the SAP include pharmaceutical, biologic, and radio-pharmaceutical products not approved for sale in Canada.
Facts sheets, forms and guidance documents
Clinical trials
If you are interested to participate in a clinical trial, ask your doctor if there is an appropriate clinical trial for your condition in your region.
If you are aware of clinical trial on Myelofibrosis please share it with us.